Enhancing the Extraordinary
Our Story
Founder's Vision
Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business.
Our Science
Technology designed to generate CAR T cells that deliver more durable outcomes for patients with cancer.
Our Pipeline
Our pipeline targets hematologic malignancies and solid tumors with significant unmet medical need.
Dedicated to Patients
An unwavering focus on science guides our mission to deliver transformative CAR T-cell therapies for patients with solid tumors and hematologic malignancies.
Learn MoreLatest News
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical trial of
View All NewsJoin Our Team
At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.
Join our team of ambitious Lyellites who are committed to defeating cancer through innovation.
See Open Positions